secwatch.observer — SEC 8-K summary
======================================

Issuer:     MoonLake Immunotherapeutics (MLTX)
CIK:        0001821586
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001213900-23-065274
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MoonLake reports Q2 cash $501.8M after $460M offering; positive Phase 2 MIRA data in HS
--------------------------------------------------------------------------------

- Raised ~$460M gross in upsized public offering (8M shares at $50); cash & equivalents $501.8M at June 30, 2023.
- Positive Phase 2 MIRA trial met primary endpoint HiSCR75 at week 12; sonelokimab showed highest clinical activity among tested therapies.
- Completed randomization of 200 patients in Phase 2 ARGO PsA trial ahead of schedule; top-line 12-week data expected H1 Nov 2023.
- R&D expenses $8.7M, G&A $4.5M for Q2 2023; no revenue (clinical-stage biotech).
- Upcoming catalysts: MIRA 24-week data mid-Oct, ARGO 12-week data Nov, End of Phase 2 FDA meeting Dec 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1821586/000121390023065274/0001213900-23-065274-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1821586/000121390023065274/ea183237-8k_moonlake.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-065274

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer